How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

597 results for

Free Thyroxine Index

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Pilates Program in Female Adolescent With Eating Disorders

(BIA). Parameters evaluated: Weight (kg); Total Body Water (L); Protein (kg); Minerals (kg); Body Fat Mass (kg); Soft Lean Mass (kg); Fat Free Mass (kg); Skeletal Muscle Mass (kg); Body Mass Index (kg/m2); Percent Body Fat (%); Bone Mineral Contect (kg). Changes in physical fitness - ALPHA-Fitness Battery. [ Time Frame: 3 times (week 0, week 10, week 20). ] ALPHA-Fitness Battery (Assessing Levels of Physical Activity and Fitness) was developed to provide a set of valid, reliable, safe and feasible (...) (perceived body image) and what figure they would like to have (desired body image). The discrepancy between these two classifications represents a measure of body dissatisfaction. The degree of discrepancy varied between -8 and -1 for those who desire a thinner form and between 1 and 8 for those who desire a larger form. A score of 0 was interpreted as satisfaction with body image (Dion et al., 2015). On the other hand, the body image perception index is determined by the following formula: (Estimated

2018 Clinical Trials

142. Liver Function After Intravenous Methylprednisolone Administration

), anti-smooth muscle antibodies (ASMA), anti-mitochondrial antibodies (AMA) and anti-liver kidney-microsomal antibodies (anti-LKM) were also assessed. Thyroid evaluation included measurement of: thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), and serum antithyroid autoantibodies including anti-thyroid peroxidase (aTPO), thyroglobulin antibodies (aTG), thyroid-binding inhibitory immunoglobulin (TBII). According to EUGOGO recommendations: patients with moderate (...) of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03667157 Sponsors and Collaborators Medical University of Warsaw Investigators Layout table for investigator information Principal Investigator: Piotr Miśkiewicz, MD, PhD Medical University of Warsaw More Information Go to Publications automatically indexed to this study

2018 Clinical Trials

143. Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer

, the microbiome and immune regulation, gut, vaginal and uterine microbiota profiles will be characterized and potential associations with body mass index (BMI), pre-treatment TIL numbers, clonality of TILs and change in the number and phenotype of TILs will be investigated. Secondary clinical objectives include (1) of the pathologic response rate after one cycle of pembrolizumab following hysterectomy and surgical staging in stage I/II, serous/clear cell EC and stage III, G3 (serous, clear cell (...) of Immune and Obesity/Inflammation EC Signatures with TILs [ Time Frame: 3 weeks ] Compare possible associations of immune and obesity/inflammation EC signatures with (1) Body Mass Index (BMI) (2) pre-treatment TIL numbers (3) clonality of TILs and (4) change in number and phenotype of TILs. Correlation of Microbiota Profiles with TILs [ Time Frame: 3 weeks ] Compare possible associations of gut, vaginal and uterine microbiota profiles with (1) BMI (2) pre-treatment TIL numbers (3) clonality of TILs

2018 Clinical Trials

144. Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

-Hodgkin Lymphoma Drug: Cyclophosphamide Drug: Doxorubicin Hydrochloride Drug: Etoposide Biological: Nivolumab Drug: Prednisone Biological: Rituximab Drug: Vincristine Sulfate Phase 2 Detailed Description: PRIMARY OBJECTIVES: I. To determine 2-year progression-free survival (PFS) of nivolumab in combination with DA-REPOCH with short course nivolumab maintenance. SECONDARY OBJECTIVES: I. To determine the objective response rate (ORR), complete response (CR) rate, and duration of response to nivolumab (...) tumor and microenvironment expression of PD-L1 and microenvironment expression of PD-1 with PFS. III. To correlate cell of origin, MYC and Bcl-2 expression, Epstein-Barr virus (EBV)-positivity, and Ki67 proliferation index with response to treatment. IV. To determine the effect of nivolumab in combination with DA-REPOCH on immune cell subsets in the peripheral blood over time. V. To correlate circulating tumor (ct) deoxyribonucleic acid (DNA) with disease response by positron emission tomography

2018 Clinical Trials

145. Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab

in the breast from randomization to definitive surgery. - Residual invasive breast cancer defined based on hematoxylin and eosin evaluation of the complete resected breast specimen following completion of neoadjuvant systemic therapy by pathological assessment. Residual Cancer Burden (RCB) [ Time Frame: 16 weeks from randomization ] Proportion of subjects with RCB 0-I, II or III from randomization to definitive surgery. -Residual Cancer Burden defined based on the RCB index, a component of four pathological (...) surgery). Event free survival [ Time Frame: 36 months from randomization ] Mean difference in time (in months) from randomization to any of the following events progression of disease that precludes surgery, local or distant recurrence, or death due to any cause. Invasive disease-free survival (IDFS) [ Time Frame: 33 months from surgery ] Mean difference in time (in months) from date of surgery (date of no disease) to the first documentation of invasive progressive disease or death. Overall survival

2018 Clinical Trials

146. Levothyroxine Replacement Therapy and overuse: A Timely Diagnostic Approach. (Abstract)

hypothyroidism.Among the 291 individuals, 114 became hypothyroid (group A), while 177 subjects remained euthyroid off LT4 (group B; 39.2% vs. 60.8%, p < 0.001). The groups were comparable regarding sex, family history, age, body mass index, duration of treatment, basal TSH and free thyroxine values, thyroid volume, and presence of thyroid autoantibodies. However, diffuse inhomogeneous echogenicity on ultrasound examination was significantly higher (p < 0.001) in group A.These findings suggest considerable overuse (...) factors of long-term LT4 supplementation.A prospective clinical cohort follow-up study was carried out. In 291 subjects (84% females) aged 48 ± 16 years on LT4 replacement therapy without a solid diagnosis of hypothyroidism being provided, the treatment was paused. At the beginning and after six to eight weeks of treatment discontinuation, thyrotropin (TSH) and free thyroxine levels were assessed, and thyroid ultrasound was performed. A TSH value of ≥4.5 IU/mL was considered as underlying

2018 Thyroid

147. Effects of short term hypothyroidism on the lipid transfer to HDL and other parameters related to lipoprotein metabolism in patients submitted to thyroidectomy for thyroid cancer. (Abstract)

a short period of overt hypothyroidism.Eighteen women (age 44 ± 11 years; body mass index 27.9 ± 5.2 kg/m2) were studied before total thyroidectomy for thyroid cancer, when they were euthyroid, and after thyroidectomy, in overt hypothyroidism for three weeks, following levothyroxine withdrawal for performance of a whole-body scan.Thyrotropin and free thyroxine confirmed hypothyroidism; low thyroglobulin and radioiodine uptake indicated near absence of thyroid tissue. LDL cholesterol (125 ± 35 vs. 167

2018 Thyroid

148. SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

-free survival for patients with recurrent or new second primary Head and Neck Squamous Cell Carcinoma (HNSCC). Condition or disease Intervention/treatment Phase Head and Neck Squamous Cell Carcinoma (HNSCC) Drug: Pembrolizumab Radiation: Stereotactic Body Radiation Therapy (SBRT) Phase 2 Detailed Description: Safety Run-In: To evaluate the safety of the addition of pembrolizumab (anti PD-1 immunotherapy) to re-irradiation with SBRT for patients with recurrent or new second primary head and neck (...) squamous cell carcinoma (HNSCC). Phase II: To compare progression-free survival (PFS) for patients with recurrent or new second primary head and neck squamous cell carcinoma with SBRT re-irradiation with or without pembrolizumab. OUTLINE: Safety Run-In: Patients receive SBRT over 2 weeks and then receive pembrolizumab every 3 weeks for up to 2 years. Phase II: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive SBRT over 2 weeks and then receive pembrolizumab every 3 weeks for up

2018 Clinical Trials

149. Effects of Infrared Laser Moxibustion on Cancer-related Fatigue in Breast Cancer Patients

count <60,000/μL,hemoglobin <8 g/dL, or leukocyte count<3000/μL) Abnormal findings in a thyroid function test (abnormal level of free thyroxine and thyroid stimulating hormone <0.1 μIU/ml or TSH> 5.1 μIU/ml) Having received acupuncture for any indication in the previous 4 weeks or having received acupuncture test within the past 6 months. Untreated major depressive disorder and suicidal ideations. Pregnant or planning to become pregnant Contacts and Locations Go to Information from the National (...) -7 not significant, 8-10 subclinical, and 11-21 clinically significant depression/anxiety. Stress [ Time Frame: 0week; 3weeks;6weeks; 12weeks; 18weeks ] The Chinese version of 10-Item Perceived Stress Scale (PSS-10) : It is a 10-item instrument and each question is rated on a 5-point Likert scale (0 = never to 4 = very often). A higher score indicates greater stress. Insomnia [ Time Frame: 0week; 3weeks;6weeks; 12weeks; 18weeks ] The Chinese version of the Pittsburgh Sleep Quality Index (PSQI

2018 Clinical Trials

150. First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect

and ketones by dipstick and Microscopic examination for part C will be reported. Part B: Number of subjects with abnormal Hormone Assessment [ Time Frame: Days -1 and 16 ] Number of subjects with abnormal Hormone Assessments including Luteinizing hormone (LH), Follicle stimulating hormone (FSH), Total Testosterone, Dihydrotestosterone (DHT), Adrenocorticotropic hormone (ACTH), Thyroid stimulating hormone (TSH), cortisol, Triiodothyronine (T3) and Free Thyroxine (T4) will be reported. Part A: Number (...) if the investigator, in consultation with the Medical Monitor, agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. Subjects with Body weight >=50.0 kilograms (Kg) (110 lbs.) and body mass index (BMI) within the range 18.5 to 31.0 kilograms per square meter (inclusive). Only male subjects are eligible for this study. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those

2018 Clinical Trials

151. Effect of Evolocumab on Vascular Function

of the study in the judgment of the investigator. Other fibrate therapy (and derivatives) are prohibited Prior use of PCSK9 inhibition treatment other than evolocumab or use of evolocumab < 12 weeks prior to final lipid screening Untreated or inadequately treated hyperthyroidism or hypothyroidism as defined by thyroid stimulating hormone (TSH) < lower limit of normal (LLN) or > 1.5 times the upper limit of normal (ULN), respectively, and free thyroxine (T4) levels that are outside normal range at final (...) ischemic attack (TIA) symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication with ankle-brachial index (ABI) < 0.85, or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease, or artery stenosis ≥50% by angiography Fasting LDL-C ≥ 70 mg/dL (≥ 1.8 mmol/L) or non-HDL-C ≥ 100 mg/dL (≥ 2.6mmol/L) on optimized background lipid lowering therapy (please see Appendix 14.3.) Stable background lipid lowering therapy for at least 4 weeks

2018 Clinical Trials

152. Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer

medication Drug: Paclitaxel Chemotherapy medication Drug: Liposomal Doxorubicin Chemotherapy medication Outcome Measures Go to Primary Outcome Measures : Overall survival (OS) [ Time Frame: from randomization to the date of death, assessed up to 44 months ] The combination of pembrolizumab and chemotherapy is expected to increase overall survival with respect to chemotherapy alone Secondary Outcome Measures : Progression free survival (PFS) [ Time Frame: from randomization to the date of radiological (...) /clinical progression of disease or death, assessed up to 44 months ] The combination of pembrolizumab and chemotherapy is expected to increase progression free survival with respect to chemotherapy alone Response rate [ Time Frame: 44 months ] The combination of pembrolizumab and chemotherapy is expected to increase response rate with respect to chemotherapy alone. Adverse events [ Time Frame: 44 months ] Incidence of adverse events, according to the National Cancer Institute Common Toxicity Criteria

2018 Clinical Trials

153. Josef Ressel Centre Perinatal Programming

Index in kg/m^2). Fat mass will be measured by air displacement plethysmography (ADP) system using whole body densitometry to determine body composition (fat and fat-free mass) using a PEA-POD™ and BOD-POD™ (COSMED Company USA). Change in energy content of mature breast milk [ Time Frame: from 8 to 16 weeks of life ] Change in energy content of 3 ml mature breast milk will be determined by MIRIS HMA™ Human Milk Analyzer (Miris Holding AB, Sweden) in kcal/dL. Samples will be measured twice and mean (...) . Breastfeeding in the first year of life appears to be a protective measure against risks for obesity development. Objective: of the "Josef Ressel Centre for Early Life Metabolic Programming of Dispositions of Obesity" is to identify maternal and infant predictors of metabolic risk in childhood obesity. The main considerations of modifiable factors are early infant nutrition, 24-hours-drinking-volume, the velocity of infant weight gain, in relation to infant fat mass and fat free mass, to biomarker

2018 Clinical Trials

154. Prevalence of subclinical hypothyroidism in adults visiting primary health-care setting in Riyadh Full Text available with Trip Pro

Prevalence of subclinical hypothyroidism in adults visiting primary health-care setting in Riyadh Background and objectives: Subclinical hypothyroidism is an asymptomatic condition with normal thyroxin and raised thyroid stimulating hormone (TSH) level. The objective of the study was to determine the prevalence of subclinical hypothyroidism in primary health care (PHC) settings in Riyadh and explore the relationship of TSH level with age, gender, family history, body mass index, and co-morbid (...) conditions. Subjects and methods: A cross-sectional study of adult visitors to nine satellites PHC clinics in military housing in Riyadh was carried out. TSH concentration and free T4 levels were measured. Data were collected by nurses and physicians during routine clinical practice in primary care. Descriptive analysis was performed on all variables in study, and relationships were explored using chi-square, t-test, analysis of variance, and linear regression. Results: A total of 340 out of 394

2018 Journal of community hospital internal medicine perspectives

155. Association Between Thyroid Function and Development of Different Obesity Phenotypes in Euthyroid Adults: A Nine-Year Follow-Up. (Abstract)

population-based cohort study, the Tehran Thyroid Study. Participants were categorized into four obesity phenotypes based on body mass index and metabolic status. To investigate the associations of thyrotropin and free thyroxine (fT4) with incidence of different obesity phenotypes across the study period, a multivariate approach based on a generalized estimating equation method was used.At baseline, individuals with the metabolically healthy normal weight (MHNW) phenotype had higher serum fT4 levels (1.2

2018 Thyroid

156. Management of Thyroid Cancer

Differentiated thyroid cancer* EBRT External beam radiotherapy EORTC European Organisation for Research and Treatment of Cancer ETA European Thyroid Association FACS Fluorescent activated cell sorter FNMTC Familial non-medullary thyroid cancer FDG Fluoro-deoxy-glucose FKGL Flesch-Kincaid Grade Level FMTC Familial medullary thyroid cancer FNAB Fine-needle aspiration biopsy FNAC Fine-needle aspiration cytology FRAX Fracture Risk Assessment Tool FTC Follicular thyroid cancer* FT4 free thyroxine FVPTC follicular

2014 British Thyroid Association

157. Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Patient

of this article, please visit: www.aace.com/reprints. Copyright © 2013 AACE. AbbreviA tions AACe = American Association of Clinical Endocrinologists; ACs = American College of Surgery; AsMbs = American Association of Metabolic and Bariatric Surgery; bAC = blood alcohol content; beD = binge eating disorder; beL = best evidence level; bMi = body mass index; bPD-Ds = biliopancreatic diversion with duodenal switch; CCs = clinical case series; CK = creatine kinase; CPAP = continuous posi- tive airway pressure; CPG (...) ? (R72-74) evidence base (Q1-7) references introDUCtion Obesity continues to be a major public health problem in the United States, with more than one-third of adults considered obese in 2009-2010, as defined by a body mass index (BMI) =30 kg/m 2 (1 [EL 3, SS]). Obesity has been associated with an increased hazard ratio for all-cause mortality (2 [EL 3, SS]), as well as significant medical and psychological co-morbidity. Indeed, obesity is not only a chronic medical condition but should be regarded

2013 American Association of Clinical Endocrinologists

159. Clinical Practice Guidelines for Hypothyroidism in Adults

is the metabolically available moiety (70), have been developed, and assess- ment of serum free T 4 has now largely replaced measure- ment of serum total T 4 as a measure of thyroid status. These methods include the serum free T 4 index, which is derived as the product of total T 4 and a thyroid hormone binding ratio, and the direct immunoassay of free T 4 after ultrafil - tration or equilibrium dialysis of serum or after addition of anti-T 4 antibody to serum (71). Table 6 Assessment of Free Thyroxine Test Method (...) 4 vs. total T 4 1011992 R8 Using free T 4 to monitor L-thyroxine treatment 1012 R9 Estimating serum free T 4 in pregnancy 1012 R10 Prohibition against using T 3 to diagnose hypothyroidism 1012 R11 Measuring TSH in hospitalized patients 1012 R12 Serum T 4 vs. TSH for management of central hypothyroidism 1012 Q5 When should TSH levels be measured in patients being treated for hypothyroidism? 1012 R13 When to measure TSH in patients taking L-thyroxine for hypothyroidism 1012 Q6 What should

2012 American Association of Clinical Endocrinologists

160. SNMMI Procedure Standard for Therapy of Thyroid Disease with 131I (Sodium Iodide) 3.0

University Medical Center, Nashville, Tennessee; 11 Beth Israel Deaconess Medical Center, Boston, Massachusetts; 12 Mallinckrodt Institute of Radiology, St. Louis, Missouri; 13 Jacobi Medical Center, Bronx, New York; 14 Vanderbilt University, Nashville, Tennessee; and 15 Cedars-Sinai Medical Center, Los Angeles, California INDEX Preamble 1 I. Introduction: patient management, licensure 2 II. Goals 2 III. De?nitions: risk levels 2 IV. Common clinical indications 3 V. Quali?cations and responsibilities (...) therapy. The consent form should include TABLE 1 Pharmaceuticals Blocking Radioiodine Uptake Type of medication Recommended time of withdrawal Thionamide medications (e.g., propylthiouracil, methimazole carbimazole) 3d Multivitamins containing iodide 7–10 d Natural or synthetic thyroid hormones 10–14 d for triiodothyronine 3–4 wk for thyroxine Kelp, agar, carrageenan, Lugol solution 2–3 wk, depending on iodide content Saturated solution of potassium iodide 2–3wk Topical iodine (e.g., surgical skin

2012 Society of Nuclear Medicine and Molecular Imaging

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>